Uses spatial proteomics combined with advanced microscopy, machine vision, and AI to map molecular interactions within biological samples at unprecedented resolution. This technology enables the identification of novel therapeutic targets and accelerates drug discovery, addressing the limitations of traditional methods in understanding complex disease mechanisms.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug discovery methods, such as genomics and transcriptomics, often fail to deliver cost-effective results. A comprehensive understanding of protein-protein networks within cells is crucial for determining the mechanisms of action of potential therapeutics, but existing methods lack the necessary resolution and spatial context.
Solution
Micrographia Bio is developing a spatial proteomics platform that combines advanced microscopy, machine vision, and AI to visualize and map molecular interactions within biological samples at an unprecedented resolution. This deeptech imaging platform serves as an intelligent, autonomous system for determining the true mechanism of action of potential therapeutics. By imaging the proteome and analyzing therapeutic molecular function, Micrographia Bio aims to radically improve the probability of success in drug discovery and advance internal pipeline therapeutic candidates focused on fundamental cellular pathways. The platform harnesses a novel strategy for highly multiplexed microscopy and state-of-the-art machine-intelligent computer vision.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery and development.
Features
- Highly multiplexed microscopy for detailed protein visualization
- Machine-intelligent computer vision for image analysis
- Spatial proteomics platform for mapping molecular interactions
- AI-driven analysis to determine therapeutic mechanisms of action
- Identification of novel therapeutic targets